Celyad shared encouraging data from its early-stage dose-escalation study assessing its chimeric antigen receptor T-cell therapy candidate CYAD-01 in patients with blood cancers and solid tumors who have not undergone preconditioning chemotherapy. The results were presented at the annual meeting of the American Society of Hematology.
Celyad reports on data from early-stage study for CAR T-cell candidate
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.